Literature DB >> 20852065

A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity.

Katie J Doores1, Zara Fulton, Vu Hong, Mitul K Patel, Christopher N Scanlan, Mark R Wormald, M G Finn, Dennis R Burton, Ian A Wilson, Benjamin G Davis.   

Abstract

Antibody 2G12 uniquely neutralizes a broad range of HIV-1 isolates by binding the high-mannose glycans on the HIV-1 surface glycoprotein, gp120. Antigens that resemble these natural epitopes of 2G12 would be highly desirable components for an HIV-1 vaccine. However, host-produced (self)-carbohydrate motifs have been unsuccessful so far at eliciting 2G12-like antibodies that cross-react with gp120. Based on the surprising observation that 2G12 binds nonproteinaceous monosaccharide D-fructose with higher affinity than D-mannose, we show here that a designed set of nonself, synthetic monosaccharides are potent antigens. When introduced to the terminus of the D1 arm of protein glycans recognized by 2G12, their antigenicity is significantly enhanced. Logical variation of these unnatural sugars pinpointed key modifications, and the molecular basis of this increased antigenicity was elucidated using high-resolution crystallographic analyses. Virus-like particle protein conjugates containing such nonself glycans are bound more tightly by 2G12. As immunogens they elicit higher titers of antibodies than those immunogenic conjugates containing the self D1 glycan motif. These antibodies generated from nonself immunogens also cross-react with this self motif, which is found in the glycan shield, when it is presented in a range of different conjugates and glycans. However, these antibodies did not bind this glycan motif when present on gp120.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20852065      PMCID: PMC2951454          DOI: 10.1073/pnas.1002717107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  Viral persistence: HIV's strategies of immune system evasion.

Authors:  Welkin E Johnson; Ronald C Desrosiers
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

2.  Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.

Authors:  E O Saphire; P W Parren; R Pantophlet; M B Zwick; G M Morris; P M Rudd; R A Dwek; R L Stanfield; D R Burton; I A Wilson
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

3.  Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds.

Authors:  Rena D Astronomo; Eiton Kaltgrad; Andrew K Udit; Sheng-Kai Wang; Katie J Doores; Cheng-Yuan Huang; Ralph Pantophlet; James C Paulson; Chi-Huey Wong; M G Finn; Dennis R Burton
Journal:  Chem Biol       Date:  2010-04-23

4.  A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.

Authors:  Robert Pejchal; Johannes S Gach; Florence M Brunel; Rosa M Cardoso; Robyn L Stanfield; Philip E Dawson; Dennis R Burton; Michael B Zwick; Ian A Wilson
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

Review 5.  HIV-1 and influenza antibodies: seeing antigens in new ways.

Authors:  Peter D Kwong; Ian A Wilson
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

6.  Analysis and optimization of copper-catalyzed azide-alkyne cycloaddition for bioconjugation.

Authors:  Vu Hong; Stanislav I Presolski; Celia Ma; M G Finn
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

7.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120.

Authors:  Rena D Astronomo; Hing-Ken Lee; Christopher N Scanlan; Ralph Pantophlet; Cheng-Yuan Huang; Ian A Wilson; Ola Blixt; Raymond A Dwek; Chi-Huey Wong; Dennis R Burton
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

10.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

View more
  40 in total

Review 1.  Recent strategies targeting HIV glycans in vaccine design.

Authors:  Satoru Horiya; Iain S MacPherson; Isaac J Krauss
Journal:  Nat Chem Biol       Date:  2014-12       Impact factor: 15.040

2.  Chemical and Biophysical Approaches for Complete Characterization of Lectin-Carbohydrate Interactions.

Authors:  Sabrina Lusvarghi; Rodolfo Ghirlando; Jack R Davison; Carole A Bewley
Journal:  Methods Enzymol       Date:  2017-07-23       Impact factor: 1.600

Review 3.  Designing synthetic vaccines for HIV.

Authors:  Alberto Fernández-Tejada; Barton F Haynes; Samuel J Danishefsky
Journal:  Expert Rev Vaccines       Date:  2015-03-31       Impact factor: 5.217

4.  The High Content of Fructose in Human Semen Competitively Inhibits Broad and Potent Antivirals That Target High-Mannose Glycans.

Authors:  Jacklyn Johnson; Manuel G Flores; John Rosa; Changze Han; Alicia M Salvi; Kris A DeMali; Jennifer R Jagnow; Amy Sparks; Hillel Haim
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

5.  AIDS/HIV. Host controls of HIV neutralizing antibodies.

Authors:  Barton F Haynes; Laurent Verkoczy
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

6.  2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.

Authors:  Katie J Doores; Michael Huber; Khoa M Le; Sheng-Kai Wang; Colleen Doyle-Cooper; Anthony Cooper; Ralph Pantophlet; Chi-Huey Wong; David Nemazee; Dennis R Burton
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

7.  Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.

Authors:  Tyler D Moeller; Kevin B Weyant; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 8.  Glycomaterials for probing host-pathogen interactions and the immune response.

Authors:  Mia L Huang; Christopher J Fisher; Kamil Godula
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04

Review 9.  Synthetic carbohydrate antigens for HIV vaccine design.

Authors:  Lai-Xi Wang
Journal:  Curr Opin Chem Biol       Date:  2013-12       Impact factor: 8.822

Review 10.  Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.

Authors:  Jean-Philippe Julien; Peter S Lee; Ian A Wilson
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.